Latest news and press releases about Relmada Therapeutics, Inc. (RLMD): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourett...
Price
| Price | $4.22 |
| Market Cap | $443M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.14 |
| EV / EBITDA | -6.71 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -47.52% |
| Return on Invested Capital | -30.78% |
| Return on Assets | -28.27% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACET · ACRV · CBUS · FBIO · IMUX · LITS · PMVP
Explore sector: Healthcare · Biotechnology
More sections of RLMD: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks